Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glycosaminoglycans may help postpone peritoneal failure in long-term continuous ambulatory peritoneal dialysis (CAPD)

This article was originally published in Clinica

Executive Summary

Administering glycosaminoglycans to patients on long-term continuous ambulatory peritoneal dialysis (CAPD) may help maintain the efficiency of the treatment, say Italian researchers in the Lancet (September 16th). Previous observations had shown that glycosaminoglycans have a protective effect on peritoneal structure and function in diabetic and other experimental rats.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel